Company / Free Cash Flow per Share
Enliven Therapeutics, Inc. Free Cash Flow per Share History
FY2019-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow per Share
-$1.56
FY2024
5-year range
-$10.46 / -$1.56
FY2020-FY2024
Trend
+10.0%
vs FY2023
Sector context
#122 of 192
Health Care
What the data says
At $-1.56, Enliven Therapeutics, Inc.'s free cash flow per share ranks #122 of 192 in the Health Care sector. Improved from $-10.46 to $-1.56 over the past 2 years.
Based on SEC 10-K filings.
-1.56 in FY2024.
Improved from $-10.46 to $-1.56 over the past 2 years.
Health Care sector context is included.
Free Cash Flow per Share over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#122 of 192 in Health CareTop 64% of 192This company -$1.56 Sector average $3.32
▼
-146.9% below sector average
Key checks
Key Insights
- In FY2024, free cash flow per share increased 10.0% year-over-year.
- Ranks #122 out of 192 companies in the Health Care sector.
- Lowest free cash flow per share in the period was in FY2019.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 7.84 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash Flow per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | -$1.56 | +10.0% |
| FY2023 | -$1.73 | +83.5% |
| FY2022 | -$10.46 | -384.5% |
| FY2021 | -$2.16 | +19.6% |
| FY2020 | -$2.69 | +91.4% |
| FY2019 | -$31.34 | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026